Autoinflammatory & rare systemic diseases
Long‐Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor–Associated Periodic Syndrome: Results From a Phase III Trial
Authors' conclusion
Control of disease activity, with low flare incidence, was maintained with long-term canakinumab treatment in patients with TRAPS during the 72-week final epoch of the CLUSTER study, with no new safety findings.
Study context
- Population
- Patients with tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in the final phase (epoch 4) of CLUSTER51 completed
- Participants
- 53 patients
- Comparison
- Canakinumab 150 or 300 mg q4w or every 8 weeks; results by cumulative weight-adjusted dose <36 vs ≥36 mg/kg
- Outcome
- No or minimal disease activity (physician global assessment)
- Follow-up
- End of epoch 4 (72 weeks)
Methodological detailslong-term extension, 72-week
- Long-term extension
- 72-week
Main finding
As reported in the abstract
Patients achieving no or minimal disease activity
>94%
Further findings
Serum amyloid A, median (largely unchanged) · End of study
Safety
- No unexpected safety findings were identified
Original publication
Long‐Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor–Associated Periodic Syndrome: Results From a Phase III Trial. Arthritis Rheumatol. Published 8 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →